Details

Autor(en) / Beteiligte

• Lang, Gabriele E.
• Stahl, Andreas
• Voegeler, Jessica
• Quiering, Claudia
• Zaremba, Laureen
• Lorenz, Katrin
• Spital, Georg
• Liakopoulos, Sandra

Titel

Observational outcomes in proliferative diabetic retinopathy patients following treatment with ranibizumab, panretinal laser photocoagulation or combination therapy – The non‐interventional second year follow‐up to the PRIDE study

Ist Teil von

• Acta ophthalmologica (Oxford, England), 2022-03, Vol.100 (2), p.e578-e587

Ort / Verlag

England: Wiley Subscription Services, Inc

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• Purpose Ranibizumab monotherapy showed stronger effects on area of retinal neovascularization (NV) reduction while offering better visual acuity (VA) results than panretinal laser photocoagulation (PRP) monotherapy during the first 12 months of the PRIDE study. The second year of PRIDE was an observational, non‐interventional follow‐up, performed to evaluate long‐term anatomical and functional outcomes in proliferative diabetic retinopathy (PDR) patients under real‐life conditions, prior to the approval of ranibizumab for PDR. Methods Seventy‐three PDR patients (28 from the ranibizumab group; 20 from the PRP group; 25 from the combination group) were included in the observational follow‐up phase and treated at the investigators discretion. Visual acuity (VA) measurements and retinal imaging were performed at Months 12, 18 and 24. Results Mean (± SD) NV area in the ranibizumab monotherapy and combination follow‐up groups increased from 3.16 ± 4.30 mm2 and 1.13 ± 2.78 mm2 at Month 12 to 6.09 ± 10.79 mm2 and 2.14 ± 4.41 mm2 at Month 18 and 10.00 ± 17.63 mm2 and 3.26 ± 7.05 mm2 at Month 24, respectively. In the PRP follow‐up group, NV area declined from 5.44 ± 14.55 mm2 at Month 12 to 1.22 ± 1.67 mm2 at Month 18, but increased again to 4.05 ± 11.66 mm2 at Month 24. During the observational phase, only 2 (6;8) patients in the ranibizumab (PRP;combination) follow‐up group were treated with anti‐VEGF medications, while 17 (6;10) patients received PRP laser therapy. Conclusion Discontinuation of ranibizumab treatment in PDR patients may result in an increase of NV area and VA loss. Tight monitoring of disease activity and continued treatment beyond the first year is needed to maintain disease control.